Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules

molecule
Atomwise will start by developing AI-generated molecules targeting Pellino E3 ubiquitin ligases, known to regulate the innate and adaptive immune systems. (UCSF)

Atomwise has inked a discovery deal potentially totaling more than $1 billion with South Korean biotech Bridge Biotherapeutics that will see it turn its artificial intelligence programs upon up to 13 small-molecule generation programs in inflammation.

“Bridge is a recognized biotech leader and has successfully out-licensed development programs to global partners such as Boehringer Ingelheim,” said Atomwise’s co-founder and CEO, Abraham Heifets, who described the project as the company’s first partnership in Korea.

“Our team has been impressed by their ability to consistently bring new therapies to the clinic and look forward to a long-term relationship,” Heifets said in a statement

RELATED: Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M

Atomwise will start working to develop AI-generated molecules focused on Pellino E3 ubiquitin ligases—which are known to regulate the innate and adaptive immune systems—as well as other targets nominated by Bridge. 

RELATED: New Atomwise offshoot X-37 raises $14.5M to shepherd AI-designed drugs

Atomwise will receive upfront, milestone and royalty payments based on the success of each individual research program. 

Suggested Articles

Shortly after announcing plans to transform itself into a digital, “cloud-first” drugmaker, Takeda has extended its agreements with Seqster.

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.